FGL1 and non-small cell lung carcinoma: Our study revealed a significant increase in FGL1 expression in NSCLC, suggesting that FGL1 could serve as both a novel biomarker for immunotherapy and a therapeutic target in NSCLC, with substantial potential for clinical translation.